Jeffrey I Weitz

List of Publications by Citations

486 papers	48,203 citations	95 h-index	212 g-index
538 ext. papers	56,468 ext. citations	10.4 avg, IF	7.63 L-index

#	Paper	IF	Citations
486	Edoxaban versus warfarin in patients with atrial fibrillation. *New England Journal of Medicine*, **2013**, 369, 2093-104	59.2	3215
485	Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. *Lancet, The*, **2014**, 383, 955-62	40	2823
484	COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review. *Journal of the American College of Cardiology*, **2020**, 75, 2950-2973	15.1	1682
483	Oral apixaban for the treatment of acute venous thromboembolism. *New England Journal of Medicine*, **2013**, 369, 799-808	59.2	1495
482	Low-molecular-weight heparins. *New England Journal of Medicine*, **1997**, 337, 688-98	59.2	1303
481	Idarucizumab for Dabigatran Reversal. *New England Journal of Medicine*, **2015**, 373, 511-20	59.2	1223
480	Derivation of a Simple Clinical Model to Categorize Patients Probability of Pulmonary Embolism: Increasing the Models Utility with the SimpliRED D-dimer. *Thrombosis and Haemostasis*, **2000**, 83, 416-420	7	1098
479	The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. *European Heart Journal*, **2018**, 39, 1330-1393	9.5	1094
478	A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. *New England Journal of Medicine*, **1996**, 334, 677-81	59.2	983
477	Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. *Circulation*, **2002**, 105, 1650-5	16.7	907
476	Apixaban for extended treatment of venous thromboembolism. *New England Journal of Medicine*, **2013**, 368, 699-708	59.2	882
475	A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. *New England Journal of Medicine*, **1999**, 340, 901-7	59.2	876
474	Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. *Journal of Clinical Investigation*, **1990**, 86, 385-91	15.9	864
473	Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. *New England Journal of Medicine*, **2018**, 378, 615-624	59.2	806
472	Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest*, **2012**, 141, e24S-e43S	5.3	651
471	Idarucizumab for Dabigatran Reversal - Full Cohort Analysis. *New England Journal of Medicine*, **2017**, 377, 431-441	59.2	639
470	Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review. *Circulation*, **1996**, 94, 3026-49	16.7	617

469	Use of a clinical model for safe management of patients with suspected pulmonary embolism. *Annals of Internal Medicine*, **1998**, 129, 997-1005	8	613
468	Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. *New England Journal of Medicine*, **2003**, 349, 631-9	59.2	609
467	Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. *New England Journal of Medicine*, **1997**, 337, 657-62	59.2	584
466	Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). *Chest*, **2008**, 133, 141S-159S	5.3	560
465	Accuracy of clinical assessment of deep-vein thrombosis. *Lancet, The*, **1995**, 345, 1326-30	40	556
464	Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. *Blood*, **2005**, 105, 1734-41	2.2	444
463	Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source. *New England Journal of Medicine*, **2018**, 378, 2191-2201	59.2	432
462	Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. *New England Journal of Medicine*, **2011**, 365, 2167-77	59.2	423
461	Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development. *Clinical Pharmacokinetics*, **2009**, 48, 1-22	6.2	404
460	Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. *New England Journal of Medicine*, **2017**, 376, 1211-1222	59.2	397
459	Thrombosis: a major contributor to global disease burden. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2014**, 34, 2363-71	9.4	377
458	Factor XI antisense oligonucleotide for prevention of venous thrombosis. *New England Journal of Medicine*, **2015**, 372, 232-40	59.2	358
457	Complement receptor type three (CD11b/CD18) of human polymorphonuclear leukocytes recognizes fibrinogen. *Proceedings of the National Academy of Sciences of the United States of America*, **1988**, 85, 7734-8	11.5	357
456	Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. *Lancet, The*, **2000**, 355, 1936-42	40	343
455	Safety of withholding heparin in pregnant women with a history of venous thromboembolism. Recurrence of Clot in This Pregnancy Study Group. *New England Journal of Medicine*, **2000**, 343, 1439-44	59.2	336
454	The postthrombotic syndrome: evidence-based prevention, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. *Circulation*, **2014**, 130, 1636-61	16.7	331
453	Homocysteine-Induced Endoplasmic Reticulum Stress and Growth Arrest Leads to Specific Changes in Gene Expression in Human Vascular Endothelial Cells. *Blood*, **1999**, 94, 959-967	2.2	292
452	Neutrophil extracellular traps promote thrombin generation through platelet-dependent and platelet-independent mechanisms. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2014**, 34, 1977-84	9.4	289

451	The lectin-like domain of thrombomodulin confers protection from neutrophil-mediated tissue damage by suppressing adhesion molecule expression via nuclear factor kappaB and mitogen-activated protein kinase pathways. *Journal of Experimental Medicine*, **2002**, 196, 565-77	16.6	287
450	Optimal Duration of Oral Anticoagulant Therapy: A Randomized Trial Comparing Four Weeks with Three Months of Warfarin in Patients with Proximal Deep Vein Thrombosis. *Thrombosis and Haemostasis*, **1995**, 74, 606-611	7	284
449	Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease. *Thrombosis and Haemostasis*, **2013**, 110, 1087-107	7	278
448	Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. *Thrombosis and Haemostasis*, **2010**, 104, 633-41	7	263
447	Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest*, **2012**, 141, e89S-e119S	5.3	262
446	Pulmonary surfactant-associated protein A enhances the surface activity of lipid extract surfactant and reverses inhibition by blood proteins in vitro. *Biochemistry*, **1990**, 29, 8424-9	3.2	252
445	Medical device-induced thrombosis: what causes it and how can we prevent it?. *Journal of Thrombosis and Haemostasis*, **2015**, 13 Suppl 1, S72-81	15.4	240
444	CD11c/CD18 on neutrophils recognizes a domain at the N terminus of the A alpha chain of fibrinogen. *Proceedings of the National Academy of Sciences of the United States of America*, **1991**, 88, 1044-8	11.5	228
443	New anticoagulants. *Circulation*, **2010**, 121, 1523-32	16.7	227
442	Prosthetic Heart Valve Thrombosis. *Journal of the American College of Cardiology*, **2016**, 68, 2670-2689	15.1	212
441	New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper. *Journal of the American College of Cardiology*, **2012**, 59, 1413-25	15.1	211
440	Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patientsÕdata. *Lancet, The*, **2002**, 359, 294-302	40	209
439	Characterization of the stress-inducing effects of homocysteine. *Biochemical Journal*, **1998**, 332 (Pt 1), 213-21	3.8	203
438	New antithrombotic drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). *Chest*, **2008**, 133, 234S-256S	5.3	186
437	Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest*, **2004**, 126, 576S-599S	5.3	181
436	Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors. *Circulation*, **1998**, 97, 544-52	16.7	180
435	Strain history dependence of the nonlinear stress response of fibrin and collagen networks. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, 12197-202	11.5	176
434	A Test in Context: D-Dimer. *Journal of the American College of Cardiology*, **2017**, 70, 2411-2420	15.1	173

433	New antithrombotic drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest*, **2012**, 141, e120S-e151S	53	170
432	Prognostic utility and characterization of cell-free DNA in patients with severe sepsis. *Critical Care*, **2012**, 16, R151	10.8	164
431	Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers. *Journal of Thrombosis and Haemostasis*, **2014**, 12, 1428-36	15.4	155
430	New anticoagulants. *Journal of Thrombosis and Haemostasis*, **2005**, 3, 1843-53	15.4	153
429	Sensitivity and specificity of a rapid whole-blood assay for D-dimer in the diagnosis of pulmonary embolism. *Annals of Internal Medicine*, **1998**, 129, 1006-11	8	153
428	A novel and rapid whole-blood assay for D-dimer in patients with clinically suspected deep vein thrombosis. *Circulation*, **1995**, 91, 2184-7	16.7	152
427	The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary. *Europace*, **2018**, 20, 1231-1242	3.9	148
426	Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. *Thrombosis and Haemostasis*, **2020**, 120, 1004-1024	7	147
425	A Histomorphometric Comparison of the Effects of Heparin and Low-Molecular-Weight Heparin on Cancellous Bone in Rats. *Blood*, **1997**, 89, 3236-3242	2.2	146
424	Coagulation assays. *Circulation*, **2005**, 112, e53-60	16.7	144
423	Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness. *New England Journal of Medicine*, **2018**, 379, 1118-1127	59.2	143
422	New anticoagulants for treatment of venous thromboembolism. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2008**, 28, 380-6	9.4	142
421	New anticoagulants. *Blood*, **2005**, 105, 453-63	2.2	136
420	General mechanisms of coagulation and targets of anticoagulants (Section I). Position Paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease. *Thrombosis and Haemostasis*, **2013**, 109, 569-79	7	134
419	Patients with severe sepsis vary markedly in their ability to generate activated protein C. *Blood*, **2004**, 104, 3958-64	2.2	131
418	Assays for measuring rivaroxaban: their suitability and limitations. *Therapeutic Drug Monitoring*, **2010**, 32, 673-9	3.2	128
417	Management of suspected deep venous thrombosis in outpatients by using clinical assessment and D-dimer testing. *Annals of Internal Medicine*, **2001**, 135, 108-11	8	128
416	Venous thrombosis. *Nature Reviews Disease Primers*, **2015**, 1, 15006	51.1	127

415	More Effective Suppression of Hemostatic System Activation in Patients Undergoing Cardiac Surgery by Heparin Dosing Based on Heparin Blood Concentrations rather than ACT. *Thrombosis and Haemostasis*, **1996**, 76, 0902-0908	7	127
414	Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. *Journal of Thrombosis and Haemostasis*, **2015**, 13, 2187-91	15.4	126
413	Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study. *Thrombosis and Haemostasis*, **2010**, 104, 642-9	7	126
412	Characterization of a mouse model for thrombomodulin deficiency. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2001**, 21, 1531-7	9.4	126
411	Idarucizumab: The Antidote for Reversal of Dabigatran. *Circulation*, **2015**, 132, 2412-22	16.7	125
410	Overview of the new oral anticoagulants: opportunities and challenges. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2015**, 35, 1056-65	9.4	124
409	Gastrointestinal bleeding with the new oral anticoagulants--defining the issues and the management strategies. *Thrombosis and Haemostasis*, **2013**, 110, 205-12	7	121
408	Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran. *Thrombosis and Haemostasis*, **2015**, 114, 198-205	7	119
407	New anticoagulant drugs. *Chest*, **2001**, 119, 95S-107S	5.3	119
406	Direct thrombin inhibitors. *Thrombosis Research*, **2002**, 106, V275-84	8.2	115
405	An evaluation of D-dimer in the diagnosis of pulmonary embolism: a randomized trial. *Annals of Internal Medicine*, **2006**, 144, 812-21	8	113
404	Direct thrombin inhibitors in acute coronary syndromes: present and future. *Circulation*, **2002**, 105, 1004-11	16.7	109
403	Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor. *Journal of Thrombosis and Haemostasis*, **2004**, 2, 743-9	15.4	108
402	New anticoagulant drugs: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest*, **2004**, 126, 265S-286S	5.3	108
401	Extending the lifetime of anticoagulant oligodeoxynucleotide aptamers in blood. *Nuclear Medicine and Biology*, **2000**, 27, 289-97	2.1	108
400	Plasma fibronectin supports hemostasis and regulates thrombosis. *Journal of Clinical Investigation*, **2014**, 124, 4281-93	15.9	108
399	Trends in Prescribing Oral Anticoagulants in Canada, 2008-2014. *Clinical Therapeutics*, **2015**, 37, 2506-2514.e4	3.5	106
398	Selective depletion of factor XI or factor XII with antisense oligonucleotides attenuates catheter thrombosis in rabbits. *Blood*, **2014**, 123, 2102-7	2.2	106

397	Ex-Vivo and In-Vitro Evidence that Low Molecular Weight Heparins Exhibit Less Binding to Plasma Proteins than Unfractionated Heparin. *Thrombosis and Haemostasis*, **1994**, 71, 300-304	7	106
396	New antithrombotic agents. *Lancet, The*, **1999**, 353, 1431-6	40	100
395	Cell-Free DNA Modulates Clot Structure and Impairs Fibrinolysis in Sepsis. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2015**, 35, 2544-53	9.4	99
394	Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study. *Thrombosis and Haemostasis*, **2018**, 118, 1439-1449	7	98
393	Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot Trial. *Circulation*, **2005**, 111, 1390-7	16.7	96
392	Evolving use of new oral anticoagulants for treatment of venous thromboembolism. *Blood*, **2014**, 124, 1020-8	2.2	95
391	Periprocedural management and approach to bleeding in patients taking dabigatran. *Circulation*, **2012**, 126, 2428-32	16.7	95
390	Anticoagulants in heart disease: current status and perspectives. *European Heart Journal*, **2007**, 28, 880-913	9.5	94
389	New oral anticoagulants in development. *Thrombosis and Haemostasis*, **2010**, 103, 62-70	7	93
388	Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. *Lancet Haematology,the*, **2016**, 3, e379-87	14.6	93
387	Reversal agents for non-vitamin K antagonist oral anticoagulants. *Nature Reviews Cardiology*, **2018**, 15, 273-281	14.8	92
386	G-protein-coupled receptors as signaling targets for antiplatelet therapy. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2009**, 29, 449-57	9.4	90
385	A diagnostic strategy involving a quantitative latex D-dimer assay reliably excludes deep venous thrombosis. *Annals of Internal Medicine*, **2003**, 138, 787-94	8	90
384	Vimentin exposed on activated platelets and platelet microparticles localizes vitronectin and plasminogen activator inhibitor complexes on their surface. *Journal of Biological Chemistry*, **2002**, 277, 7529-39	5.4	90
383	Long-term oral anticoagulant therapy in patients with unstable angina or suspected non-Q-wave myocardial infarction: organization to assess strategies for ischemic syndromes (OASIS) pilot study results. *Circulation*, **1998**, 98, 1064-70	16.7	90
382	Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin. *American Journal of Cardiology*, **1998**, 82, 12P-18P	3	89
381	A simple clinical model for the diagnosis of deep-vein thrombosis combined with impedance plethysmography: potential for an improvement in the diagnostic process. *Journal of Internal Medicine*, **1998**, 243, 15-23	10.8	89
380	The Effects of Standard and Low Molecular Weight Heparin on Bone Nodule Formation In Vitro. *Thrombosis and Haemostasis*, **1998**, 80, 413-417	7	85

379	Evidence for allosteric linkage between exosites 1 and 2 of thrombin. *Journal of Biological Chemistry*, **1997**, 272, 25493-9	5.4	84
378	Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19: JACC State-of-the-Art Review. *Journal of the American College of Cardiology*, **2021**, 77, 1903-1921	15.1	84
377	Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis. *BMJ, The*, **2019**, 366, l4363	5.9	83
376	Inferior vena cava ligation rapidly induces tissue factor expression and venous thrombosis in rats. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2009**, 29, 863-9	9.4	83
375	Therapeutic strategies for thrombosis: new targets and approaches. *Nature Reviews Drug Discovery*, **2020**, 19, 333-352	64.1	82
374	Clinical utility of a rapid whole-blood D-dimer assay in patients with cancer who present with suspected acute deep venous thrombosis. *Annals of Internal Medicine*, **1999**, 131, 417-23	8	82
373	The status of new anticoagulants. *British Journal of Haematology*, **2006**, 134, 3-19	4.5	81
372	Molecular basis for the susceptibility of fibrin-bound thrombin to inactivation by heparin cofactor ii in the presence of dermatan sulfate but not heparin. *Journal of Biological Chemistry*, **2001**, 276, 20959-65	5.4	81
371	Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial. *JAMA Internal Medicine*, **2021**, 181, 1612-1620	11.5	81
370	Emerging anticoagulants for the treatment of venous thromboembolism. *Thrombosis and Haemostasis*, **2006**, 96, 274-84	7	80
369	Oral direct factor Xa inhibitors. *Circulation Research*, **2012**, 111, 1069-78	15.7	78
368	Increased neutrophil elastase activity in cigarette smokers. *Annals of Internal Medicine*, **1987**, 107, 680-2	8	78
367	Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial. *Blood*, **2008**, 112, 4432-6	2.2	76
366	Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers. *Thrombosis and Haemostasis*, **2004**, 91, 1090-6	7	76
365	Evolving Treatments for Arterial and Venous Thrombosis: Role of the Direct Oral Anticoagulants. *Circulation Research*, **2016**, 118, 1409-24	15.7	76
364	Thrombosis: a major contributor to global disease burden. *Seminars in Thrombosis and Hemostasis*, **2014**, 40, 724-35	5.3	75
363	Laboratory Monitoring of Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation: A Review. *JAMA Cardiology*, **2017**, 2, 566-574	16.2	72
362	Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE-cancer study. *Thrombosis and Haemostasis*, **2015**, 114, 1268-76	7	71

361	Novel oral anticoagulants in gastroenterology practice. *Gastrointestinal Endoscopy*, **2013**, 78, 227-39	5.2	71
360	Mechanism of catheter thrombosis: comparison of the antithrombotic activities of fondaparinux, enoxaparin, and heparin in vitro and in vivo. *Blood*, **2011**, 118, 6667-74	2.2	71
359	Contribution of host-derived tissue factor to tumor neovascularization. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2008**, 28, 1975-81	9.4	71
358	Antithrombotic therapy in patients undergoing percutaneous coronary intervention. *Chest*, **2001**, 119, 321S-336S	5.3	71
357	Comparison of the Non-Specific Binding of Unfractionated Heparin and Low Molecular Weight Heparin (Enoxaparin) to Plasma Proteins. *Thrombosis and Haemostasis*, **1993**, 70, 625-630	7	71
356	Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial. *Lancet Haematology,the*, **2017**, 4, e105-e113	14.6	67
355	The blood compatibility challenge. Part 1: Blood-contacting medical devices: The scope of the problem. *Acta Biomaterialia*, **2019**, 94, 2-10	10.8	66
354	Rivaroxaban for secondary stroke prevention in patients with embolic strokes of undetermined source: Design of the NAVIGATE ESUS randomized trial. *European Stroke Journal*, **2016**, 1, 146-154	5.6	65
353	Delayed but not Early Treatment with DNase Reduces Organ Damage and Improves Outcome in a Murine Model of Sepsis. *Shock*, **2015**, 44, 166-72	3.4	64
352	Fibrinolytic Variables in Patients with Recurrent Venous Thrombosis: a Prospective Cohort Study. *Thrombosis and Haemostasis*, **2001**, 85, 390-394	7	63
351	Novel oral anticoagulants and reversal agents: Considerations for clinical development. *American Heart Journal*, **2015**, 169, 751-7	4.9	62
350	Exosites 1 and 2 are essential for protection of fibrin-bound thrombin from heparin-catalyzed inhibition by antithrombin and heparin cofactor II. *Journal of Biological Chemistry*, **1999**, 274, 6226-33	5.4	62
349	Meeting the unmet needs in anticoagulant therapy. *European Journal of Haematology*, **2010**, 85, 1-28	3.8	61
348	Antibody-Based Ticagrelor Reversal Agent in Healthy Volunteers. *New England Journal of Medicine*, **2019**, 380, 1825-1833	59.2	60
347	Dabigatran is Less Effective Than Warfarin at Attenuating Mechanical Heart Valve-Induced Thrombin Generation. *Journal of the American Heart Association*, **2015**, 4, e002322	6	60
346	Selective D-dimer testing for diagnosis of a first suspected episode of deep venous thrombosis: a randomized trial. *Annals of Internal Medicine*, **2013**, 158, 93-100	8	60
345	An omniphobic lubricant-infused coating produced by chemical vapor deposition of hydrophobic organosilanes attenuates clotting on catheter surfaces. *Scientific Reports*, **2017**, 7, 11639	4.9	60
344	In vitro comparison of the effect of heparin, enoxaparin and fondaparinux on tests of coagulation. *Thrombosis Research*, **2002**, 107, 241-4	8.2	60

343	A Histomorphometric Evaluation of Heparin-Induced Bone Loss After Discontinuation of Heparin Treatment in Rats. *Blood*, **1999**, 93, 1231-1236	2.2	60
342	Incorporation of vitronectin into fibrin clots. Evidence for a binding interaction between vitronectin and gamma A/gamma fibrinogen. *Journal of Biological Chemistry*, **2002**, 277, 7520-8	5.4	59
341	New developments in anticoagulants: Past, present and future. *Thrombosis and Haemostasis*, **2017**, 117, 1283-1288	7	58
340	Corn trypsin inhibitor coating attenuates the prothrombotic properties of catheters in vitro and in vivo. *Acta Biomaterialia*, **2012**, 8, 4092-100	10.8	58
339	Homocysteine-dependent alterations in mitochondrial gene expression, function and structure. Homocysteine and H2O2 act synergistically to enhance mitochondrial damage. *Journal of Biological Chemistry*, **1998**, 273, 30808-17	5.4	58
338	Zinc: an important cofactor in haemostasis and thrombosis. *Thrombosis and Haemostasis*, **2013**, 109, 421-30	7	57
337	Factor Xa and thrombin as targets for new oral anticoagulants. *Thrombosis Research*, **2011**, 127 Suppl 2, S5-S12	8.2	57
336	Beyond heparin and warfarin: the new generation of anticoagulants. *Expert Opinion on Investigational Drugs*, **2007**, 16, 271-82	5.9	57
335	Evidence that both exosites on thrombin participate in its high affinity interaction with fibrin. *Journal of Biological Chemistry*, **2003**, 278, 21584-91	5.4	56
334	Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty: The FOXTROT Randomized Clinical Trial. *JAMA - Journal of the American Medical Association*, **2020**, 323, 130-139	27.4	54
333	Type 1 plasminogen activator inhibitor binds to fibrin via vitronectin. *Journal of Biological Chemistry* , **2000**, 275, 19788-94	5.4	54
332	Lubricant-Infused Surfaces with Built-In Functional Biomolecules Exhibit Simultaneous Repellency and Tunable Cell Adhesion. *ACS Nano*, **2018**, 12, 10890-10902	16.7	54
331	Dabigatran attenuates thrombin generation to a lesser extent than warfarin: could this explain their differential effects on intracranial hemorrhage and myocardial infarction?. *Journal of Thrombosis and Thrombolysis*, **2013**, 35, 295-301	5.1	53
330	Practical management of bleeding in patients receiving non-vitamin K antagonist oral anticoagulants. *Thrombosis and Haemostasis*, **2015**, 114, 1113-26	7	52
329	The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. Design, rationale, and clinical implications. *Thrombosis and Haemostasis*, **2016**, 115, 1240-8	7	52
328	Anticoagulant-Associated Intracranial Hemorrhage in the Era of Reversal Agents. *Stroke*, **2017**, 48, 1432-1437	6.4	51
327	Long range communication between exosites 1 and 2 modulates thrombin function. *Journal of Biological Chemistry*, **2009**, 284, 25620-9	5.4	51
326	Use of a fixed activated partial thromboplastin time ratio to establish a therapeutic range for unfractionated heparin. *Archives of Internal Medicine*, **2001**, 161, 385-91		51

325	Translational success stories: development of direct thrombin inhibitors. *Circulation Research*, **2012**, 111, 920-9	15.7	50
324	The Asp(272)-Glu(282) region of platelet glycoprotein Ibalpha interacts with the heparin-binding site of alpha-thrombin and protects the enzyme from the heparin-catalyzed inhibition by antithrombin III. *Journal of Biological Chemistry*, **2000**, 275, 3887-95	5.4	50
323	Combination Antiplatelet and Oral Anticoagulant Therapy in Patients With Coronary and Peripheral Artery Disease. *Circulation*, **2019**, 139, 2170-2185	16.7	49
322	HD1, a thrombin-directed aptamer, binds exosite 1 on prothrombin with high affinity and inhibits its activation by prothrombinase. *Journal of Biological Chemistry*, **2006**, 281, 37477-85	5.4	48
321	COVID-19 coagulopathy, thrombosis, and bleeding. *Blood*, **2020**, 136, 381-383	2.2	48
320	Identification of the mechanism responsible for the increased fibrin specificity of TNK-tissue plasminogen activator relative to tissue plasminogen activator. *Journal of Biological Chemistry*, **2000**, 275, 10112-20	5.4	47
319	Factors XI and XII as Targets for New Anticoagulants. *Frontiers in Medicine*, **2017**, 4, 19	4.9	46
318	Update on heparin: what do we need to know?. *Journal of Thrombosis and Thrombolysis*, **2010**, 29, 199-207	3.1	46
317	Oncogenes as regulators of tissue factor expression in cancer: implications for tumor angiogenesis and anti-cancer therapy. *Seminars in Thrombosis and Hemostasis*, **2004**, 30, 21-30	5.3	46
316	Factor XI and factor XII as targets for new anticoagulants. *Thrombosis Research*, **2016**, 141 Suppl 2, S40-5	8.2	46
315	Risk of recurrent venous thromboembolism according to baseline risk factor profiles. *Blood Advances*, **2018**, 2, 788-796	7.8	46
314	Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis. *Blood*, **2020**, 136, 1433-1441	2.2	45
313	Bivalent binding to gammaA/gammaA' fibrin engages both exosites of thrombin and protects it from inhibition by the antithrombin-heparin complex. *Journal of Biological Chemistry*, **2008**, 283, 2470-7	5.4	45
312	A novel approach to thrombin inhibition. *Thrombosis Research*, **2003**, 109 Suppl 1, S17-22	8.2	45
311	Comparison of heparin- and dermatan sulfate-mediated catalysis of thrombin inactivation by heparin cofactor II. *Journal of Biological Chemistry*, **1999**, 274, 27597-604	5.4	45
310	Emerging anticoagulant strategies. *Blood*, **2017**, 129, 147-154	2.2	44
309	Antithrombotic Agents. *Circulation Research*, **2019**, 124, 426-436	15.7	43
308	Characteristics and Management of Patients with Venous Thromboembolism: The GARFIELD-VTE Registry. *Thrombosis and Haemostasis*, **2019**, 119, 319-327	7	43

307	Hypercoagulable states. *Critical Care Clinics*, **2011**, 27, 933-52, vii	4.5	42
306	The variable anticoagulant response to unfractionated heparin in vivo reflects binding to plasma proteins rather than clearance. *Translational Research*, **1997**, 130, 649-55		42
305	New anticoagulants for treatment of venous thromboembolism. *Circulation*, **2004**, 110, I19-26	16.7	42
304	Effect of nonspecific binding to plasma proteins on the antithrombin activities of unfractionated heparin, low-molecular-weight heparin, and dermatan sulfate. *Circulation*, **1997**, 95, 118-24	16.7	42
303	Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease. *Nature Reviews Cardiology*, **2020**, 17, 242-257	14.8	41
302	Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. *Lancet Haematology,the*, **2016**, 3, e228-36	14.6	41
301	Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism. Rationale for and design of the EINSTEIN CHOICE study. *Thrombosis and Haemostasis*, **2015**, 114, 645-50	7	40
300	Prognostic significance of thrombocytopenia during hirudin and heparin therapy in acute coronary syndrome without ST elevation: Organization to Assess Strategies for Ischemic Syndromes (OASIS-2)study. *Circulation*, **2001**, 103, 643-50	16.7	40
299	Investigation of the anticoagulant mechanisms of a covalent antithrombin-heparin complex. *Journal of Biological Chemistry*, **1998**, 273, 34730-6	5.4	40
298	Thromboprophylaxis in surgical patients. *Canadian Journal of Surgery*, **2003**, 46, 129-35	2	39
297	The Effect of Thrombin Inhibitors on Tissue Plasminogen Activator Induced Thrombolysis in a Rat Model. *Thrombosis and Haemostasis*, **1992**, 68, 064-068	7	39
296	Antiphospholipid antibodies and recurrent thrombosis after a first unprovoked venous thromboembolism. *Blood*, **2018**, 131, 2151-2160	2.2	38
295	Characterization of Patients with Embolic Strokes of Undetermined Source in the NAVIGATE ESUS Randomized Trial. *Journal of Stroke and Cerebrovascular Diseases*, **2018**, 27, 1673-1682	2.8	37
294	Histidine-rich glycoprotein binds factor XIIa with high affinity and inhibits contact-initiated coagulation. *Blood*, **2011**, 117, 4134-41	2.2	37
293	Role of the tissue factor pathway in the biology of tumor initiating cells. *Thrombosis Research*, **2010**, 125 Suppl 2, S44-50	8.2	36
292	A replacement for warfarin: the search continues. *Circulation*, **2007**, 116, 131-3	16.7	36
291	Global Anticoagulant Registry in the Field - Venous Thromboembolism (GARFIELD-VTE). Rationale and design. *Thrombosis and Haemostasis*, **2016**, 116, 1172-1179	7	36
290	Binding of anti-GRP78 autoantibodies to cell surface GRP78 increases tissue factor procoagulant activity via the release of calcium from endoplasmic reticulum stores. *Journal of Biological Chemistry*, **2010**, 285, 28912-23	5.4	35

289	New anticoagulants: beyond heparin, low-molecular-weight heparin and warfarin. *British Journal of Pharmacology*, **2005**, 144, 1017-28	8.6	35
288	Structure-Function Analyses of Thrombomodulin by Gene-Targeting in Mice: The Cytoplasmic Domain Is Not Required for Normal Fetal Development. *Blood*, **1999**, 93, 3442-3450	2.2	35
287	Urgent Need to Measure Effects of Direct Oral Anticoagulants. *Circulation*, **2016**, 134, 186-8	16.7	34
286	Mechanism of catalysis of inhibition of factor IXa by antithrombin in the presence of heparin or pentasaccharide. *Journal of Biological Chemistry*, **2003**, 278, 35767-74	5.4	34
285	Antithrombotic therapy in patients undergoing coronary angioplasty. *Chest*, **1995**, 108, 486S-501S	5.3	34
284	NOAC monitoring, reversal agents, and post-approval safety and effectiveness evaluation: A cardiac safety research consortium think tank. *American Heart Journal*, **2016**, 177, 74-86	4.9	34
283	Evaluation of DNA aptamers directed to thrombin as potential thrombus imaging agents. *Nuclear Medicine and Biology*, **2003**, 30, 61-72	2.1	33
282	Mechanism of Action of Plasminogen Activators. *Thrombosis and Haemostasis*, **1999**, 82, 974-982	7	33
281	New anticoagulant strategies. Current status and future potential. *Drugs*, **1994**, 48, 485-97	12.1	33
280	New antithrombotics. *Chest*, **1995**, 108, 471S-485S	5.3	33
279	Thrombin/antithrombin III complex formation in the neonatal respiratory distress syndrome. *The American Review of Respiratory Disease*, **1992**, 145, 767-70		33
278	Histidine-rich glycoprotein binds DNA and RNA and attenuates their capacity to activate the intrinsic coagulation pathway. *Thrombosis and Haemostasis*, **2016**, 115, 89-98	7	33
277	Conductive Electrochemically Active Lubricant-Infused Nanostructured Surfaces Attenuate Coagulation and Enable Friction-Less Droplet Manipulation. *Advanced Materials Interfaces*, **2018**, 5, 1800617	4.6	32
276	Characterization of the interactions of plasminogen and tissue and vampire bat plasminogen activators with fibrinogen, fibrin, and the complex of D-dimer noncovalently linked to fragment E. *Journal of Biological Chemistry*, **1998**, 273, 18292-9	5.4	32
275	Heparan sulfate: Antithrombotic or not?. *Journal of Clinical Investigation*, **2003**, 111, 952-954	15.9	32
274	Parenteral anticoagulants in heart disease: current status and perspectives (Section II). Position paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease. *Thrombosis and Haemostasis*, **2013**, 109, 769-86	7	31
273	Vasoflux, a new anticoagulant with a novel mechanism of action. *Circulation*, **1999**, 99, 682-9	16.7	31
272	Arterial thrombosis is accelerated in mice deficient in histidine-rich glycoprotein. *Blood*, **2015**, 125, 2712-22	9.2	30

271	New oral anticoagulants: which one should my patient use?. *Hematology American Society of Hematology Education Program*, **2012**, 2012, 536-540	3.1	30
270	Antithrombin-heparin covalent complex: a possible alternative to heparin for arterial thrombosis prevention. *Circulation*, **2002**, 106, 261-5	16.7	30
269	Idarucizumab for dabigatran overdose. *Clinical Toxicology*, **2016**, 54, 644-6	2.9	29
268	Insights into the role of thrombin in the pathogenesis of recurrent ischaemia after acute coronary syndrome. *Thrombosis and Haemostasis*, **2014**, 112, 924-31	7	29
267	A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery. *Thrombosis and Haemostasis*, **2010**, 104, 1150-7	7	29
266	Thrombophilia and new anticoagulant drugs. *Hematology American Society of Hematology Education Program*, **2004**, 2004, 424-38	3.1	29
265	Selection and characterization of a DNA aptamer inhibiting coagulation factor XIa. *Scientific Reports* , **2017**, 7, 2102	4.9	28
264	Expert Consensus Guidelines for Stocking of Antidotes in Hospitals That Provide Emergency Care. *Annals of Emergency Medicine*, **2018**, 71, 314-325.e1	2.1	28
263	New oral anticoagulants: a view from the laboratory. *American Journal of Hematology*, **2012**, 87 Suppl 1, S133-6	7.1	28
262	Multimerin 1 binds factor V and activated factor V with high affinity and inhibits thrombin generation. *Thrombosis and Haemostasis*, **2008**, 100, 1058-1067	7	28
261	Beyond heparin and aspirin: new treatments for unstable angina and non-Q-wave myocardial infarction. *Archives of Internal Medicine*, **2000**, 160, 749-58		28
260	Effects of Intermittent Pneumatic Calf Compression On Postoperative Thrombin and Plasmin Activity. *Thrombosis and Haemostasis*, **1986**, 56, 198-201	7	28
259	A high affinity interaction of plasminogen with fibrin is not essential for efficient activation by tissue-type plasminogen activator. *Journal of Biological Chemistry*, **2012**, 287, 4652-61	5.4	27
258	Hypercoagulable states. *Clinics in Chest Medicine*, **2010**, 31, 659-73	5.3	27
257	New anticoagulant therapy. *Annual Review of Medicine*, **2005**, 56, 63-77	17.4	27
256	Localization of the thrombin-binding domain on prothrombin fragment 2. *Journal of Biological Chemistry*, **1998**, 273, 8932-9	5.4	27
255	Role of phenotypic and genetic testing in managing clopidogrel therapy. *Blood*, **2014**, 124, 689-99	2.2	26
254	Life-threatening thrombosis in mice with targeted Arg48-to-Cys mutation of the heparin-binding domain of antithrombin. *Circulation Research*, **2003**, 93, 1120-6	15.7	26

253	Effect of fibrinogen degradation products and lung ground substance on surfactant function. *Neonatology*, **1990**, 57, 325-33	4	26
252	Decreased thrombin activity of fibrin clots prepared in cord plasma compared with adult plasma. *Pediatric Research*, **1996**, 39, 826-30	3.2	25
251	Novel antithrombotic strategies for treatment of venous thromboembolism. *Blood*, **2020**, 135, 351-359	2.2	25
250	The contact activation system as a potential therapeutic target in patients with COVID-19. *Research and Practice in Thrombosis and Haemostasis*, **2020**, 4, 500-505	5.1	24
249	HD1, a thrombin- and prothrombin-binding DNA aptamer, inhibits thrombin generation by attenuating prothrombin activation and thrombin feedback reactions. *Thrombosis and Haemostasis*, **2010**, 103, 83-93	7	24
248	Direct thrombin inhibitors in cardiac disease. *Cardiovascular Toxicology*, **2003**, 3, 13-25	3.4	24
247	Conformational changes in thrombin when complexed by serpins. *Journal of Biological Chemistry*, **2001**, 276, 44828-34	5.4	24
246	New antithrombotic agents. *Chest*, **1998**, 114, 715S-727S	5.3	24
245	Activation of blood coagulation by plaque rupture: mechanisms and prevention. *American Journal of Cardiology*, **1995**, 75, 18B-22B	3	24
244	Single and multi-functional coating strategies for enhancing the biocompatibility and tissue integration of blood-contacting medical implants. *Biomaterials*, **2020**, 258, 120291	15.6	24
243	Advances in Antithrombotic Therapy. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2019**, 39, 7-12	9.4	24
242	Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients. *Journal of the American College of Cardiology*, **2020**, 75, 3140-3147	15.1	23
241	2017 Scientific Sessions Sol Sherry Distinguished Lecture in Thrombosis: Factor XI as a Target for New Anticoagulants. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2018**, 38, 304-310	9.4	23
240	Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post-hoc analysis of the Hokusai-VTE Cancer study. *Journal of Thrombosis and Haemostasis*, **2019**, 17, 1866-1874	15.4	23
239	Phase 2 study of TAK-442, an oral factor Xa inhibitor, in patients following acute coronary syndrome. *Thrombosis and Haemostasis*, **2014**, 111, 1141-52	7	23
238	Anticoagulation therapy. Dabigatran and risk of myocardial infarction. *Nature Reviews Cardiology*, **2012**, 9, 260-2	14.8	23
237	Batroxobin binds fibrin with higher affinity and promotes clot expansion to a greater extent than thrombin. *Journal of Biological Chemistry*, **2013**, 288, 16862-16871	5.4	23
236	Histidine-rich glycoprotein binds fibrin(ogen) with high affinity and competes with thrombin for binding to the gamma-chain. *Journal of Biological Chemistry*, **2011**, 286, 30314-30323	5.4	23

235	New anticoagulants: current status and future potential. *American Journal of Cardiovascular Drugs*, **2003**, 3, 201-9	4	23
234	Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. *Lancet Haematology,the*, **2016**, 3, e437-45	14.6	23
233	Linking Endogenous Factor Xa Activity, a Biologically Relevant Pharmacodynamic Marker, to Edoxaban Plasma Concentrations and Clinical Outcomes in the ENGAGE AF-TIMI 48 Trial. *Circulation* , **2018**, 138, 1963-1973	16.7	23
232	Abelacimab for Prevention of Venous Thromboembolism. *New England Journal of Medicine*, **2021**, 385, 609-617	59.2	23
231	Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease. *Circulation Research*, **2019**, 124, 416-425	15.7	22
230	Identification of Dp71 isoforms in the platelet membrane cytoskeleton. Potential role in thrombin-mediated platelet adhesion. *Journal of Biological Chemistry*, **2002**, 277, 47106-13	5.4	22
229	Measurement of Markers of Activated Coagulation in Antithrombin III Deficient Subjects. *Thrombosis and Haemostasis*, **1992**, 67, 542-544	7	22
228	Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial. *Thrombosis and Haemostasis*, **2016**, 116, 747-53	7	21
227	Catheter thrombosis and percutaneous coronary intervention: fundamental perspectives on blood, artificial surfaces and antithrombotic drugs. *Journal of Thrombosis and Thrombolysis*, **2009**, 28, 366-80	5.1	21
226	Emerging anticoagulant drugs. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2003**, 23, 1491-500	9.4	21
225	Pharmacology and clinical potential of direct thrombin inhibitors. *Current Pharmaceutical Design*, **2005**, 11, 3877-84	3.3	21
224	Oral anticoagulants in coronary heart disease (Section IV). Position paper of the ESC Working Group on Thrombosis - Task Force on Anticoagulants in Heart Disease. *Thrombosis and Haemostasis*, **2016**, 115, 685-711	7	21
223	Gastrointestinal Bleeding With Edoxaban Versus Warfarin: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis In Myocardial Infarction). *Circulation: Cardiovascular Quality and Outcomes*, **2018**, 11, e003998	5.8	20
222	Periprocedural management of new oral anticoagulants in patients undergoing atrial fibrillation ablation. *Circulation*, **2014**, 129, 1688-94	16.7	20
221	Hirudin causes more bleeding than heparin in a rabbit ear bleeding model. *Translational Research*, **1998**, 132, 181-5		20
220	Ximelagatran: the first oral direct thrombin inhibitor. *Expert Opinion on Investigational Drugs*, **2004**, 13, 403-13	5.9	20
219	Hypersulfated low molecular weight heparin with reduced affinity for antithrombin acts as an anticoagulant by inhibiting intrinsic tenase and prothrombinase. *Journal of Biological Chemistry*, **2001**, 276, 9755-61	5.4	20
218	Limited fibrin specificity of tissue-type plasminogen activator and its potential link to bleeding. *Journal of Vascular and Interventional Radiology*, **1995**, 6, 19S-23S	2.4	20

217	Dabigatran etexilate for prevention of venous thromboembolism. *Thrombosis and Haemostasis*, **2009**, 101, 2-4	7	20
216	Zinc promotes clot stability by accelerating clot formation and modifying fibrin structure. *Thrombosis and Haemostasis*, **2016**, 115, 533-42	7	20
215	North American Thrombosis Forum, AF Action Initiative Consensus Document. *American Journal of Medicine*, **2016**, 129, S1-S29	2.4	19
214	The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V-Special Situations. *Thrombosis and Haemostasis*, **2019**, 119, 14-38	7	19
213	Dabigatran Reversal with Idarucizumab. *New England Journal of Medicine*, **2017**, 377, 1691-2	59.2	18
212	Upper Extremity DVT versus Lower Extremity DVT: Perspectives from the GARFIELD-VTE Registry. *Thrombosis and Haemostasis*, **2019**, 119, 1365-1372	7	18
211	Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: An analysis of the randomized, double-blind Hokusai-VTE trial. *Thrombosis Research*, **2018**, 162, 7-14	8.2	18
210	Biofunctional Lubricant-Infused Vascular Grafts Functionalized with Silanized Bio-Inks Suppress Thrombin Generation and Promote Endothelialization. *ACS Biomaterials Science and Engineering*, **2019**, 5, 6485-6496	5.5	18
209	Markers of inflammation and activation of coagulation are associated with anaemia in antiretroviral-treated HIV disease. *Aids*, **2014**, 28, 1791-6	3.5	18
208	Surface modification with polyethylene glycol-corn trypsin inhibitor conjugate to inhibit the contact factor pathway on blood-contacting surfaces. *Acta Biomaterialia*, **2011**, 7, 4177-86	10.8	18
207	Mechanisms responsible for catalysis of the inhibition of factor Xa or thrombin by antithrombin using a covalent antithrombin-heparin complex. *Journal of Biological Chemistry*, **2003**, 278, 23398-409	5.4	18
206	New anticoagulants. *Seminars in Thrombosis and Hemostasis*, **2003**, 29, 619-31	5.3	18
205	Heparin and angiogenesis: size matters!. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2003**, 23, 1954-5	9.4	18
204	Anticoagulation therapy patterns for acute treatment of venous thromboembolism in GARFIELD-VTE patients. *Journal of Thrombosis and Haemostasis*, **2019**, 17, 1694-1706	15.4	17
203	Recent advances in the treatment of venous thromboembolism in the era of the direct oral anticoagulants. *F1000Research*, **2017**, 6, 985	3.6	17
202	Comparison of the effect of coagulation and platelet function impairments on various mouse bleeding models. *Thrombosis and Haemostasis*, **2014**, 112, 412-8	7	17
201	The real decoy: an antidote for factor Xa-directed anticoagulants. *Circulation Research*, **2013**, 113, 954-7	15.7	17
200	Thrombin-activable fibrinolysis inhibitor attenuates (DD)E-mediated stimulation of plasminogen activation by reducing the affinity of (DD)E for tissue plasminogen activator. A potential mechanism for enhancing the fibrin specificity of tissue plasminogen activator. *Journal of Biological Chemistry*, **2000**, 275, 36612-20	5.4	17

199	Advances in Therapy and the Management of Antithrombotic Drugs for Venous Thromboembolism. *Hematology American Society of Hematology Education Program*, **2000**, 266-284	3.1	17
198	Do Coagulation Screening Tests Detect Increased Generation of Thrombin and Plasmin in Sick Newborn Infants?. *Thrombosis and Haemostasis*, **1993**, 69, 418-421	7	17
197	Lubricant-Infused PET Grafts with Built-In Biofunctional Nanoprobes Attenuate Thrombin Generation and Promote Targeted Binding of Cells. *Small*, **2019**, 15, e1905562	11	17
196	Clinical implications of incidental venous thromboembolism in cancer patients. *European Respiratory Journal*, **2020**, 55,	13.6	16
195	Heparin synergistically enhances interleukin-11 signaling through up-regulation of the MAPK pathway. *Journal of Biological Chemistry*, **2006**, 281, 20780-20787	5.4	16
194	Comparison of the ecarin chromogenic assay and diluted thrombin time for quantification of dabigatran concentrations. *Journal of Thrombosis and Haemostasis*, **2017**, 15, 2377-2387	15.4	15
193	Cancer associated thrombosis in everyday practice: perspectives from GARFIELD-VTE. *Journal of Thrombosis and Thrombolysis*, **2020**, 50, 267-277	5.1	15
192	Isolated Distal Deep Vein Thrombosis: Perspectives from the GARFIELD-VTE Registry. *Thrombosis and Haemostasis*, **2019**, 119, 1675-1685	7	15
191	Non-vitamin K antagonist oral anticoagulants: an appeal for consensus on terminology. *Chest*, **2014**, 145, 1177-1178	5.3	15
190	Zn2+ mediates high affinity binding of heparin to the domain of fibrinogen. *Journal of Biological Chemistry*, **2013**, 288, 29394-402	5.4	15
189	Zinc delays clot lysis by attenuating plasminogen activation and plasmin-mediated fibrin degradation. *Thrombosis and Haemostasis*, **2015**, 113, 1278-88	7	15
188	Modes and consequences of thrombin interaction with fibrin. *Biophysical Chemistry*, **2004**, 112, 277-84	3.5	15
187	Low-dose warfarin in rehabilitating stroke survivors. *Thrombosis Research*, **2002**, 107, 287-90	8.2	15
186	Expanding use of new oral anticoagulants. *F1000prime Reports*, **2014**, 6, 93		15
185	New anticoagulants: Moving beyond the direct oral anticoagulants. *Journal of Thrombosis and Haemostasis*, **2021**, 19, 20-29	15.4	15
184	Platelet polyphosphate: the long and the short of it. *Blood*, **2017**, 129, 1574-1575	2.2	14
183	Incident Atrial Fibrillation, Dementia and the Role of Anticoagulation: A Population-Based Cohort Study. *Thrombosis and Haemostasis*, **2019**, 119, 981-991	7	14
182	Potential of new anticoagulants in patients with cancer. *Thrombosis Research*, **2010**, 125 Suppl 2, S30-5	8.2	14

181	Antithrombins: their potential as antithrombotic agents. *Annual Review of Medicine*, **1992**, 43, 9-16	17.4	14
180	Milvexian for the Prevention of Venous Thromboembolism. *New England Journal of Medicine*, **2021**, 385, 2161-2172	59.2	14
179	Biomarkers of coagulation, endothelial function, and fibrinolysis in critically ill patients with COVID-19: A single-center prospective longitudinal study. *Journal of Thrombosis and Haemostasis*, **2021**, 19, 1546-1557	15.4	14
178	Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Results from the AMPLIFY trial. *Thrombosis and Haemostasis*, **2016**, 116, 1159-1164	7	14
177	Reversal of Direct Oral Anticoagulants: Current Status and Future Directions. *Seminars in Respiratory and Critical Care Medicine*, **2017**, 38, 40-50	3.9	13
176	Factor XI antisense oligonucleotide for venous thrombosis. *New England Journal of Medicine*, **2015**, 372, 1672	59.2	13
175	Antithrombotic activity of the novel oral anticoagulant, Tecarfarin [Sodium 3-[4-((1,1,1,3,3,3-hexafluoro-2-methylpropan-2-yloxy) carbonyl) benzyl]-2-oxo-2H-chromen-4-olate] in animal models. *Thrombosis Research*, **2010**, 126, e383-8	8.2	13
174	Unanswered questions in venous thromboembolism. *Thrombosis Research*, **2009**, 123 Suppl 4, S2-S10	8.2	13
173	A non-anticoagulant synthetic pentasaccharide reduces inflammation in a murine model of kidney ischemia-reperfusion injury. *Thrombosis and Haemostasis*, **2006**, 96, 802-806	7	13
172	The rate of fibrinopeptide B release modulates the rate of clot formation: a study with an acquired inhibitor to fibrinopeptide B release. *British Journal of Haematology*, **1991**, 79, 296-301	4.5	13
171	Edoxaban For Long-Term Treatment Of Venous Thromboembolism In Cancer Patients. *Blood*, **2013**, 122, 211-211	2.2	13
170	Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy. A sub-analysis of the AMPLIFY trial. *Thrombosis and Haemostasis*, **2016**, 115, 809-16	7	13
169	Molecular basis for the resistance of fibrin-bound thrombin to inactivation by heparin/serpin complexes. *Advances in Experimental Medicine and Biology*, **1997**, 425, 55-66	3.6	13
168	Dabigatran Reversal With Idarucizumab in Patients With Renal Impairment. *Journal of the American College of Cardiology*, **2019**, 74, 1760-1768	15.1	12
167	Variation in the Association between Antineoplastic Therapies and Venous Thromboembolism in Patients with Active Cancer. *Thrombosis and Haemostasis*, **2020**, 120, 847-856	7	12
166	Subtle differences in commercial heparins can have serious consequences for cardiopulmonary bypass patients: A randomized controlled trial. *Journal of Thoracic and Cardiovascular Surgery*, **2012**, 144, 944-950.e3	1.5	12
165	Factor XIII Prevents Pulmonary Emboli in Mice by Stabilizing Deep Vein Thrombi. *Thrombosis and Haemostasis*, **2019**, 119, 992-999	7	11
164	Thromboprophylaxis with Rivaroxaban in Acutely Ill Medical Patients with Renal Impairment: Insights from the MAGELLAN and MARINER Trials. *Thrombosis and Haemostasis*, **2020**, 120, 515-524	7	11

163	Peri-operative Adverse Outcomes in Patients with Atrial Fibrillation Taking Warfarin or Edoxaban: Analysis of the ENGAGE AF-TIMI 48 Trial. *Thrombosis and Haemostasis*, **2018**, 118, 1001-1008	7	11
162	Targeted gene sequencing identifies variants in the protein C and endothelial protein C receptor genes in patients with unprovoked venous thromboembolism. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2013**, 33, 2674-81	9.4	11
161	Timing the First Postoperative Dose of Anticoagulants: Lessons Learned From Clinical Trials. *Chest*, **2015**, 148, 587-595	5.3	11
160	Only high levels of dabigatran attenuate catheter thrombosis in vitro and in rabbits. *Thrombosis and Haemostasis*, **2014**, 112, 79-86	7	11
159	By increasing the affinity of heparin for fibrin, Zn(2+) promotes the formation of a ternary heparin-thrombin-fibrin complex that protects thrombin from inhibition by antithrombin. *Biochemistry*, **2012**, 51, 7964-73	3.2	11
158	Randomized, Parallel Group, Multicenter, Multinational Study Evaluating Safety of DU-176b Compared with Warfarin in Subjects with Non-Valvular Atrial Fibrillation. *Blood*, **2008**, 112, 33-33	2.2	11
157	FIBRIN CLOT LYSIS BY TISSUE PLASMINOGEN ACTIVATOR (tPA) IS IMPAIRED IN PLASMA FROM PEDIATRIC PATIENTS UNDERGOING ORTHOTOPIC LIVER TRANSPLANTATION. *Transplantation*, **1995**, 60, 144-146	1.8	11
156	Incorporating edoxaban into the choice of anticoagulants for atrial fibrillation. *Thrombosis and Haemostasis*, **2016**, 115, 257-70	7	11
155	Mortality Risk Profiles for Sepsis: A Novel Longitudinal and Multivariable Approach **2019**, 1, e0032		11
154	Anticoagulation therapy in 2015: where we are and where we are going. *Journal of Thrombosis and Thrombolysis*, **2015**, 39, 264-72	5.1	10
153	Comparative effectiveness of oral anticoagulants in venous thromboembolism: GARFIELD-VTE. *Thrombosis Research*, **2020**, 191, 103-112	8.2	10
152	Benefits and risks of extended treatment of venous thromboembolism with rivaroxaban or with aspirin. *Thrombosis Research*, **2018**, 168, 121-129	8.2	10
151	Dual surface modification with PEG and corn trypsin inhibitor: effect of PEG:CTI ratio on protein resistance and anticoagulant properties. *Journal of Biomedical Materials Research - Part A*, **2012**, 100, 856-62	5.4	10
150	Choosing wisely: The impact of patient selection on efficacy and safety outcomes in the EINSTEIN-DVT/PE and AMPLIFY trials. *Thrombosis Research*, **2017**, 149, 29-37	8.2	10
149	New oral anticoagulants for thromboprophylaxis in patients having hip or knee arthroplasty. *BMJ, The*, **2011**, 342, c7270	5.9	10
148	Incorporation of fragment X into fibrin clots renders them more susceptible to lysis by plasmin. *Biochemistry*, **2006**, 45, 4257-65	3.2	10
147	Interaction of low molecular weight heparin with ketorolac. *Translational Research*, **1996**, 127, 583-7		10
146	Dabigatran Reversal With Idarucizumab in Patients Requiring Urgent Surgery: A Subanalysis of the RE-VERSE AD Study. *Annals of Surgery*, **2021**, 274, e204-e211	7.8	10

145	Factor XI Inhibition to Uncouple Thrombosis From Hemostasis: JACC Review Topic of the Week. *Journal of the American College of Cardiology*, **2021**, 78, 625-631	15.1	10
144	Initial treatment of venous thromboembolism. *Thrombosis and Haemostasis*, **2006**, 96, 242-50	7	9
143	Glycosaminoglycans bind factor Xa in a Ca2+-dependent fashion and modulate its catalytic activity. *Biochemistry*, **2003**, 42, 13091-8	3.2	9
142	Heparan sulfate: antithrombotic or not?. *Journal of Clinical Investigation*, **2003**, 111, 952-4	15.9	9
141	Optimizing the safety of treatment for venous thromboembolism in the era of direct oral anticoagulants. *Polish Archives of Internal Medicine*, **2016**, 126, 688-696	1.9	9
140	Standard and Low Molecular Weight Heparin Have no Effect on Tissue Plasminogen Activator Induced Plasma Clot Lysis or Fibrinogenolysis. *Thrombosis and Haemostasis*, **1991**, 65, 541-544	7	9
139	Long-Term Management of Venous Thromboembolism: Lessons from EINSTEIN CHOICE and Other Extension Trials. *Thrombosis and Haemostasis*, **2019**, 119, 689-694	7	9
138	Characteristics and Outcomes in Patients with Venous Thromboembolism Taking Concomitant Anti-Platelet Agents and Anticoagulants in the AMPLIFY Trial. *Thrombosis and Haemostasis*, **2019**, 119, 461-466	7	9
137	Effect of Different Doses of Acetylsalicylic Acid on the Antithrombotic Activity of Clopidogrel in a Mouse Arterial Thrombosis Model. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2018**, 38, 2338-2344	8.4	9
136	Reduced plasminogen binding and delayed activation render γ-fibrin more resistant to lysis than α-fibrin. *Journal of Biological Chemistry*, **2014**, 289, 27494-503	5.4	8
135	Modification of polyurethane with polyethylene glycol-corn trypsin inhibitor for inhibition of factor XIIa in blood contact. *Journal of Biomaterials Science, Polymer Edition*, **2012**, 23, 1981-93	3.5	8
134	Inhibition of osteolytic bone metastasis by unfractionated heparin. *Clinical and Experimental Metastasis*, **2008**, 25, 903-11	4.7	8
133	Randomized comparison of a novel anticoagulant, vasoflux, and heparin as adjunctive therapy to streptokinase for acute myocardial infarction: results of the VITAL study (Vasoflux International Trial for Acute Myocardial Infarction Lysis). *American Heart Journal*, **2001**, 142, 237-43	4.9	8
132	Dabigatran and Argatroban Diametrically Modulate Thrombin Exosite Function. *PLoS ONE*, **2016**, 11, e0157471	3.7	8
131	Mechanistic Basis for the Differential Effects of Rivaroxaban and Apixaban on Global Tests of Coagulation. *TH Open*, **2018**, 2, e190-e201	2.7	8
130	Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in patients with non-valvular atrial fibrillation. *Journal of Thrombosis and Thrombolysis*, **2020**, 50, 20-29	5.1	7
129	Outpatient Management in Patients with Venous Thromboembolism with Edoxaban: A Post Hoc Analysis of the Hokusai-VTE Study. *Thrombosis and Haemostasis*, **2017**, 117, 2406-2414	7	7
128	Leukocyte urokinase plasminogen activator receptor and PSGL1 play a role in endogenous arterial fibrinolysis. *Thrombosis and Haemostasis*, **2009**, 102, 1212-8	7	7

127	Otamixaban in acute coronary syndromes. *Lancet, The*, **2009**, 374, 762-4	40	7
126	Selective factor Xa inhibition for thromboprophylaxis. *Lancet, The*, **2008**, 372, 6-8	40	7
125	Spotlight on unmet needs in stroke prevention: The PIONEER AF-PCI, NAVIGATE ESUS and GALILEO trials. *Thrombosis and Haemostasis*, **2016**, 116, S33-S40	7	7
124	Long-Term Risk for Major Bleeding During Extended Oral Anticoagulant Therapy for First Unprovoked Venous Thromboembolism : A Systematic Review and Meta-analysis. *Annals of Internal Medicine*, **2021**, 174, 1420-1429	8	7
123	New oral anticoagulants: which one should my patient use?. *Hematology American Society of Hematology Education Program*, **2012**, 2012, 536-40	3.1	7
122	Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE AD□study. *Journal of Medical Economics*, **2017**, 20, 435-442	2.4	6
121	Exosite 2-Directed Ligands Attenuate Protein C Activation by the Thrombin-Thrombomodulin Complex. *Biochemistry*, **2017**, 56, 3119-3128	3.2	6
120	Impact of concomitant antiplatelet therapy on the efficacy and safety of direct oral anticoagulants for acute venous thromboembolism: Systematic review and meta-analysis. *Journal of Thrombosis and Haemostasis*, **2020**, 18, 1661-1671	15.4	6
119	Addressing the burden of hospital-related venous thromboembolism: the role of extended anticoagulant prophylaxis. *Journal of Thrombosis and Haemostasis*, **2018**, 16, 413-417	15.4	6
118	Global public awareness about atrial fibrillation. *Research and Practice in Thrombosis and Haemostasis*, **2018**, 2, 49-57	5.1	6
117	Screening and diagnostic clinical algorithm for paroxysmal nocturnal hemoglobinuria: Expert consensus. *European Journal of Haematology*, **2018**, 101, 3-11	3.8	6
116	Treatment Challenges in Venous Thromboembolism: An Appraisal of Rivaroxaban Studies. *Thrombosis and Haemostasis*, **2018**, 118, S23-S33	7	6
115	A randomised, double blind comparison of tecarfarin, a novel vitamin K antagonist, with warfarin. The EmbraceAC Trial. *Thrombosis and Haemostasis*, **2016**, 116, 241-50	7	6
114	Rivaroxaban plus aspirin for cardiovascular protection: Rationale for the vascular dose and dual pathway inhibition. *Thrombosis Research*, **2019**, 184, 44-49	8.2	6
113	Localization of heparin and low-molecular-weight heparin in the rat kidney. *Thrombosis and Haemostasis*, **2004**, 91, 927-34	7	6
112	Increased Risk of Death in Acutely Ill Medical Patients with Asymptomatic Proximal Deep Vein Thrombosis or Symptomatic Venous Thromboembolism: Insights from the Magellan Study. *Blood*, **2019**, 134, 163-163	2.2	6
111	The Additive Effect of Low Molecular Weight Heparins on Thrombin Inhibition by Dermatan Sulfate. *Thrombosis and Haemostasis*, **1993**, 70, 443-447	7	6
110	Hypercoagulability and coronavirus disease 2019-associated hypoxemic respiratory failure: Mechanisms and emerging management paradigms. *Journal of Trauma and Acute Care Surgery*, **2020**, 89, e177-e181	3.3	6

109	Rivaroxaban and Dabigatran for Suppression of Mechanical Heart Valve-Induced Thrombin Generation. *Annals of Thoracic Surgery*, **2020**, 110, 582-590	2.7	6
108	Factor XI as a Target for New Anticoagulants. *Hamostaseologie*, **2021**, 41, 104-110	1.9	6
107	The contact activation inhibitor AB023 in heparin-free hemodialysis: results of a randomized phase 2 clinical trial. *Blood*, **2021**, 138, 2173-2184	2.2	6
106	Pregnancy-Associated Venous Thromboembolism: Insights from GARFIELD-VTE. *TH Open*, **2021**, 5, e24-e34	2.7	6
105	MAA868 locks factor XIa in a zymogen-like state. *Blood*, **2019**, 133, 1393-1394	2.2	5
104	A Risk Assessment Tool Incorporating New Biomarkers for Cardiovascular Events in Acute Coronary Syndromes: The Organization to Assess Strategies in Ischemic Syndromes (OASIS) Risk Score. *Canadian Journal of Cardiology*, **2016**, 32, 1332-1339	3.8	5
103	Illustrated State-of-the-Art Capsules of the ISTH 2019 Congress in Melbourne, Australia. *Research and Practice in Thrombosis and Haemostasis*, **2019**, 3, 431-497	5.1	5
102	The complete N-terminal extension of heparin cofactor II is required for maximal effectiveness as a thrombin exosite 1 ligand. *BMC Biochemistry*, **2013**, 14, 6	4.8	5
101	More on acutely injured patients receiving dabigatran. *New England Journal of Medicine*, **2012**, 366, 863; author reply 864	59.2	5
100	New and emerging anticoagulant therapies for venous thromboembolism. *Current Treatment Options in Cardiovascular Medicine*, **2010**, 12, 142-55	2.1	5
99	In the presence of phospholipids, glycosaminoglycans potentiate factor Xa-mediated protein C activation by modulating factor Xa activity. *Biochemistry*, **2007**, 46, 4195-203	3.2	5
98	Antithrombin-independent anticoagulation by hypersulfated low-molecular-weight heparin. *Trends in Cardiovascular Medicine*, **2002**, 12, 281-7	6.9	5
97	Phase 2 Study of the Factor XI Antisense Inhibitor IONIS-FXI in Patients With ESRD.. *Kidney International Reports*, **2022**, 7, 200-209	4.1	5
96	Assessment of Outcomes Among Patients With Venous Thromboembolism With and Without Chronic Kidney Disease. *JAMA Network Open*, **2020**, 3, e2022886	10.4	5
95	Treatment-Dose LMWH versus Prophylactic/Intermediate Dose Heparins in High-Risk COVID-19 Inpatients: Rationale and Design of the HEP-COVID Trial. *Thrombosis and Haemostasis*, **2021**, 121, 1684-1695	7	5
94	Rivaroxaban for prevention and treatment of venous thromboembolism. *Future Cardiology*, **2019**, 15, 63-77	1.3	5
93	Polysiloxane Nanofilaments Infused with Silicone Oil Prevent Bacterial Adhesion and Suppress Thrombosis on Intranasal Splints. *ACS Biomaterials Science and Engineering*, **2021**, 7, 541-552	5.5	5
92	Identification and characterization of a factor Va-binding site on human prothrombin fragment 2. *Scientific Reports*, **2019**, 9, 2436	4.9	4

91	Activated thrombin-activatable fibrinolysis inhibitor (TAFIa) attenuates fibrin-dependent plasmin generation on thrombin-activated platelets. *Journal of Thrombosis and Haemostasis*, **2020**, 18, 2364-2376	15.4	4
90	An open-label study of the pharmacokinetics and pharmacodynamics of dabigatran etexilate 150mg once daily in Caucasian patients with moderate renal impairment undergoing primary unilateral elective total knee or hip replacement surgery. *Thrombosis Research*, **2016**, 144, 158-64	8.2	4
89	Overview of Hemostasis and Thrombosis **2018**, 1831-1842		4
88	The prothrombin time does not predict the risk of recurrent venous thromboembolism or major bleeding in rivaroxaban-treated patients. *Thrombosis Research*, **2018**, 170, 75-83	8.2	4
87	Establishing Therapeutic Equivalence of Complex Pharmaceuticals: The Case of Dabigatran. *Canadian Journal of Cardiology*, **2018**, 34, 1116-1119	3.8	4
86	Randomized phase 2 trial comparing JNJ-9375, a thrombin-directed antibody, with apixaban for prevention of venous thrombosis. *Journal of Thrombosis and Haemostasis*, **2019**, 17, 2081-2088	15.4	4
85	Theme 3: Non-invasive management of (recurrent) venous thromboembolism (VTE) and post thrombotic syndrome (PTS). *Thrombosis Research*, **2015**, 136 Suppl 1, S13-8	8.2	4
84	Genetics of coagulation: what the cardiologist needs to know. *Canadian Journal of Cardiology*, **2013**, 29, 75-88	3.8	4
83	Another oral thrombin inhibitor for stroke prevention in atrial fibrillation?. *Thrombosis and Haemostasis*, **2010**, 103, 481-3	7	4
82	Anticoagulation for ST-segment elevation myocardial infarction. *Circulation*, **2009**, 119, 1186-8	16.7	4
81	Dysfibrinogenemia in obstructive liver disease. *Journal of Pediatric Gastroenterology and Nutrition*, **1987**, 6, 967-70	2.8	4
80	Abstract 17392: Gastrointestinal Bleeding With Edoxaban versus Warfarin: Results From the ENGAGE AF-TIMI 48 Trial. *Circulation*, **2015**, 132,	16.7	4
79	Two Doses of Apixaban for the Extended Treatment of Venous Thromboembolism. *Blood*, **2012**, 120, LBA-1-LBA-1	2.2	4
78	Evaluation of a Soluble Fibrin Assay in Patients with Suspected Pulmonary Embolism. *Thrombosis and Haemostasis*, **1996**, 75, 551-554	7	4
77	Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with bioprosthetic valves. *Expert Review of Cardiovascular Therapy*, **2018**, 1-6	2.5	4
76	Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the treatment of venous thromboembolism. *Journal of Thrombosis and Thrombolysis*, **2020**, 50, 1-11	5.1	3
75	Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the prevention of venous thromboembolism. *Journal of Thrombosis and Thrombolysis*, **2020**, 50, 12-19	5.1	3
74	Influence of model-predicted rivaroxaban exposure and patient characteristics on efficacy and safety outcomes in patients with acute coronary syndrome. *Therapeutic Advances in Cardiovascular Disease*, **2019**, 13, 1753944719863641	3.4	3

73	Emerging therapies for stroke prevention in atrial fibrillation. *Country Review Ukraine*, **2005**, 7, C19-C27		3
72	New anticoagulant drugs. *Journal of Thrombosis and Thrombolysis*, **2001**, 12, 7-17	5.1	3
71	Development and application of assays for elastase-specific fibrinogen fragments. *Annals of the New York Academy of Sciences*, **1991**, 624, 154-66	6.5	3
70	Time in Therapeutic Range (TTR) and Relative Efficacy and Safety of Treatment with Apixaban or Enoxaparin/Warfarin for Acute Symptomatic Venous Thromboembolism: An Analysis of the Amplify Trial Data. *Blood*, **2014**, 124, 1543-1543	2.2	3
69	Venous thromboembolism in Asia and worldwide: Emerging insights from GARFIELD-VTE. *Thrombosis Research*, **2021**, 201, 63-72	8.2	3
68	A PoTENtial Antidote: A Prohemostatic Factor Xa Variant for Reversal of Direct Oral Anticoagulants. *Circulation Research*, **2016**, 119, 1157-1160	15.7	3
67	Provoked versus unprovoked venous thromboembolism: Findings from GARFIELD-VTE. *Research and Practice in Thrombosis and Haemostasis*, **2021**, 5, 326-341	5.1	3
66	Use of novel antithrombotic agents for COVID-19: Systematic summary of ongoing randomized controlled trials. *Journal of Thrombosis and Haemostasis*, **2021**, 19, 3080-3089	15.4	3
65	Antithrombotic Therapy in COVID-19: Systematic Summary of Ongoing or Completed Randomized Trials		3
64	Acute coronary syndromes: a focus on thrombin. *Journal of Invasive Cardiology*, **2002**, 14 Suppl B, 2B-7B	0.7	3
63	Extended Treatment of Venous Thromboembolism. *New England Journal of Medicine*, **2017**, 376, 2491-2492	59.2	2
62	Lys 42/43/44 and Arg 12 of thrombin-activable fibrinolysis inhibitor comprise a thrombomodulin exosite essential for its antifibrinolytic potential. *Thrombosis and Haemostasis*, **2017**, 117, 1509-1517	7	2
61	Direct Oral Anticoagulants for Pulmonary Embolism: Importance of Anatomical Extent. *TH Open*, **2018**, 2, e1-e7	2.7	2
60	Assessment and Management of Gastrointestinal Hemorrhage in the Setting of Direct Oral Anticoagulants: The Hematology Perspective. *American Journal of Gastroenterology Supplements (Print)*, **2016**, 3, 29-35		2
59	Hematologic Problems in the Surgical Patient: Bleeding and Thrombosis **2018**, 2304-2312.e4		2
58	The new heparins. *Coronary Artery Disease*, **1998**, 9, 65-74	1.4	2
57	Safety and Efficacy of the Contact Activation Inhibitor AB023 in Patients with End-Stage Renal Disease on Chronic Hemodialysis: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Trial. *Blood*, **2020**, 136, 23-24	2.2	2
56	Recent advances in understanding, diagnosing and treating venous thrombosis. *F1000Research*, **2020**, 9,	3.6	2

55	Advances in Therapy and the Management of Antithrombotic Drugs for Venous Thromboembolism. *Hematology American Society of Hematology Education Program*, **2000**, 2000, 266-284	3.1	2
54	Heavy menstrual bleeding in women on anticoagulant treatment for venous thromboembolism: Comparison of high- and low-dose rivaroxaban with aspirin. *Research and Practice in Thrombosis and Haemostasis*, **2021**, 5, 308-313	5.1	2
53	Risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer using edoxaban. *Journal of Thrombosis and Haemostasis*, **2021**, 19, 3008-3017	15.4	2
52	Anticoagulation in patients with kidney failure on dialysis: factor XI as a therapeutic target. *Kidney International*, **2021**, 100, 1199-1207	9.9	2
51	Bentracimab for Ticagrelor Reversal in Patients Undergoing Urgent Surgery **2022**, 1,		2
50	Response by Chan and Weitz to Letter Regarding Article, "Antithrombotic Agents: New Directions in Antithrombotic Therapy". *Circulation Research*, **2019**, 124, e119	15.7	1
49	Antithrombotic Drugs **2018**, 2168-2188		1
48	Idrabiotaparinux treatment for venous thromboembolism. *Lancet, The*, **2012**, 379, 96-8	40	1
47	Procoagulants for management of bleeding with the new oral anticoagulants. *Thrombosis and Haemostasis*, **2013**, 110, 1	7	1
46	Prevention and treatment of venous thromboembolism during pregnancy. *Catheterization and Cardiovascular Interventions*, **2009**, 74 Suppl 1, S22-6	2.7	1
45	OASIS-6: should patients with acute ST-segment elevation myocardial infarction be treated with fondaparinux?. *Nature Clinical Practice Cardiovascular Medicine*, **2006**, 3, 478-9		1
44	Neutrophils and the protein C pathway. *Blood*, **2003**, 102, 1152-1153	2.2	1
43	Deep Vein Thrombosis. *Current Treatment Options in Cardiovascular Medicine*, **1999**, 1, 43-54	2.1	1
42	Elevated Fibrinopeptide A and B Levels during Thrombolytic Therapy: Real or Artefactual?. *Thrombosis and Haemostasis*, **1996**, 75, 529-535	7	1
41	Meta-Analysis of Long-Term Risk of Recurrent Venous Thromboembolism after Stopping Anticoagulation in Men and Women with First Unprovoked Venous Thromboembolism. *Blood*, **2018**, 132, 2527-2527	2.2	1
40	Ximelagatran: the first oral direct thrombin inhibitor		1
39	Anticoagulation for Patients with Venous Thromboembolism: When is Extended Treatment Required?. *TH Open*, **2020**, 4, e446-e456	2.7	1
38	Immunothrombosis Biomarkers for Distinguishing Coronavirus Disease 2019 Patients From Noncoronavirus Disease Septic Patients With Pneumonia and for Predicting ICU Mortality. **2021**, 3, e0588		1

37	Treatment of cancer-associated thrombosis: The evolution of anticoagulant choice and clinical insights into practical management. *Critical Reviews in Oncology/Hematology*, **2021**, 157, 103125	7	1
36	Antiplatelet therapy in the management of atherothrombosis: recent clinical advances. *Blood Advances*, **2018**, 2, 1806	7.8	1
35	The influence of anemia on clinical outcomes in venous thromboembolism: Results from GARFIELD-VTE. *Thrombosis Research*, **2021**, 203, 155-162	8.2	1
34	Long-term risk of recurrent venous thromboembolism among patients receiving extended oral anticoagulant therapy for first unprovoked venous thromboembolism: A systematic review and meta-analysis. *Journal of Thrombosis and Haemostasis*, **2021**, 19, 2801-2813	15.4	1
33	Polyphosphate-induced thrombosis in mice is factor XII dependent and is attenuated by histidine-rich glycoprotein. *Blood Advances*, **2021**, 5, 3540-3551	7.8	1
32	Influence of body mass index on clinical outcomes in venous thromboembolism: Insights from GARFIELD-VTE. *Journal of Thrombosis and Haemostasis*, **2021**, 19, 3031-3043	15.4	1
31	Transparent and Highly Flexible Hierarchically Structured Polydimethylsiloxane Surfaces Suppress Bacterial Attachment and Thrombosis Under Static and Dynamic Conditions.. *Small*, **2022**, e2108112	11	1
30	Extended anticoagulant therapy in venous thromboembolism: a balanced, fractional factorial, clinical vignette-based study. *Haematologica*, **2019**, 104, e474-e477	6.6	0
29	Emerging Anticoagulant Drugs. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2007**, 27, 721-721	9.4	0
28	Zinc Enhances the Protection of Fibrin-Bound Thrombin from Antithro Inhibition.. *Blood*, **2007**, 110, 2691-2691	22	0
27	Rivaroxaban for extended thromboprophylaxis in acutely ill medical patients 75 years of age or older. *Journal of Thrombosis and Haemostasis*, **2021**, 19, 2772-2780	15.4	0
26	Evaluation of direct oral anticoagulants in superficial-vein thrombosis - Authors' reply. *Lancet Haematology,the*, **2017**, 4, e254-e255	14.6	
25	Antiplatelet Drugs in the Management of Venous Thromboembolism, Cardioembolism, Ventricular Assist Devices, and Pregnancy Complications **2019**, 1067-1077		
24	Response by Weitz and Eikelboom to Letter Regarding Article, "Urgent Need to Measure Effects of Direct Oral Anticoagulants". *Circulation*, **2016**, 134, e498	16.7	
23	Letter to the Editor: Managing Dabigatran-Related Bleeding. *Journal of Intensive Care Medicine*, **2016**, 31, 70-1	3.3	
22	- a new ISTH publishing platform for the global thrombosis and hemostasis community. *Research and Practice in Thrombosis and Haemostasis*, **2017**, 1, 6-8	5.1	
21	In high-risk patients with arthritis and previous upper GI bleeding, celecoxib vs naproxen reduced recurrent bleeding. *Annals of Internal Medicine*, **2017**, 167, JC17	8	
20	Venous Thrombosis **2013**, 619-626		

19	Changing paradigms in the management of venous thromboembolism. *The American Heart Hospital Journal*, **2006**, 4, 135-41	
18	Management of venous thromboembolism: present and future. *Circulation*, **2004**, 110, I2	16.7
17	Management of Edoxaban Therapy in Patients Undergoing Major Surgery: A Sub-Analysis of the Prospective, Observational, Multinational Emit-AF/VTE Study. *Blood*, **2021**, 138, 3024-3024	2.2
16	Advances in Therapy and the Management of Antithrombotic Drugs for Venous Thromboembolism. *Hematology American Society of Hematology Education Program*, **2000**, 2000, 266-284	3.1
15	Role of Thrombin Exosites in Protection from Inhibition by Antithrombin in the Presence of Heparin and Fibrin.. *Blood*, **2004**, 104, 1721-1721	2.2
14	Studies into the Mechanism by Which Glycosaminoglycans Potentiate Protein C Activation by Factor Xa.. *Blood*, **2004**, 104, 1724-1724	2.2
13	No Fibrinolytic Benefit of Adjunctive Anticoagulation during Arterial Thrombolysis Induced by tPA Combined with TAFIa Inhibitor in a Rabbit Arterial Thrombosis Model.. *Blood*, **2004**, 104, 2979-2979	2.2
12	Role of Plasminogen-Fibrin Interaction in Plasminogen Activation by t-PA.. *Blood*, **2004**, 104, 1737-1737	2.2
11	Zinc2+ Promotes Heparin Binding to Fibrin and Subsequent Formation of Ternary Heparin-Thrombin-Fibrin Complexes.. *Blood*, **2005**, 106, 1956-1956	2.2
10	Thrombin Aptamer HD1 Inhibits Prothrombin Activation by Binding Proexosite 1 on Prothrombin.. *Blood*, **2005**, 106, 1950-1950	2.2
9	Factor V Binding to Multimerin 1: Modulation by Factor V Activation and Binding Sites in the Factor V C1 and C2 Domains.. *Blood*, **2006**, 108, 193-193	2.2
8	Laboratory assessment of platelet function and coagulation **2008**, 19-31	
7	Medically Ill Patients with Moderate Renal Insufficiency Have More Thrombotic and Bleeding Events Than Those with Normal Renal Function: Insights from the Magellan and Mariner Trials of Extended Thrombprophylaxis. *Blood*, **2018**, 132, 1236-1236	2.2
6	Association of Bleeding Severity with Mortality with Extended Thromboprophylaxis in the Medically Ill in the Mariner Trial. *Blood*, **2019**, 134, 3669-3669	2.2
5	New antithrombotic drugs: beyond aspirin and heparin. *Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research*, **1999**, 29 Suppl S1, 68	
4	A Histomorphometric Evaluation of Heparin-Induced Bone Loss After Discontinuation of Heparin Treatment in Rats. *Blood*, **1999**, 93, 1231-1236	2.2
3	Overview of New Anticoagulant Drugs. *Fundamental and Clinical Cardiology*, **2009**, 133-154	
2	Comment on model-based meta-analysis to evaluate optimal doses of direct oral factor Xa inhibitors in atrial fibrillation patients. *Blood Advances*, **2018**, 2, 3193-3195	7.8

1	Extended treatment of venous thromboembolism. *Clinical Advances in Hematology and Oncology*, **2013**, 11, 302-4	0.6